Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week open-label safety study of asenapine in adolescents with schizophrenia
2009-018038-12Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of asenapine in schizophrenia, sponsored by Merck & Co. Primary endpoint: Long-term safety of asenapine in adolescents with schizophrenia. Started Jan 2011; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2009-018038-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018038-12.